TLR2 stimulation of intrinsic renal cells in the induction of immune-mediated glomerulonephritis.
Infection may exacerbate organ-specific autoimmune disease such as glomerulonephritis. This may occur in the absence of a measurable effect on the adaptive immune response, and the mechanisms responsible are not fully understood. To investigate this, we have studied the effect of TLR2 ligation by the synthetic ligand Pam(3)CysSK(4) on the development of glomerulonephritis in mice. We demonstrated that glomerular inflammation induced by passive administration of nephrotoxic Ab does not occur in the absence of TLR2 stimulation, with a strong synergy when Ab deposition and TLR2 stimulation occur together. Parameters of glomerular inflammation were neutrophil influx, thrombosis, and albuminuria. To investigate the relative contribution of TLR2 on bone marrow-derived cells and intrinsic renal cells, we constructed bone marrow chimeras. Nephrotoxic Ab and TLR2 ligation caused a neutrophil influx in both types of chimera above [corrected] that seen in sham chimeras totally TLR2 deficient [corrected] Albuminuria was seen in both types of chimera above that seen in sham chimeras that were totally TLR2 deficient. This was greater in chimeras with TLR2 present on bone marrow-derived cells. To find a potential mechanism by which intrinsic renal cells may contribute toward disease exacerbation, mesangial cells were studied and shown to express TLR2 and MyD88. Wild-type but not TLR2-deficient mesangial cells produced CXC chemokines in response to stimulation with Pam(3)CysSK(4). These results demonstrate that TLR2 stimulation on both bone marrow-derived and resident tissue cells plays a role in amplifying the inflammatory effects of Ab deposition in the glomerulus.
Brown
Heather J
HJ
Department of Nephrology and Transplantation, King's College London School of Medicine, Guy's Hospital, London, UK. heather.brown@kcl.ac.uk
Lock
Helen R
HR
Sacks
Steven H
SH
Robson
Michael G
MG
D048868:Adaptor Proteins, Signal Transducing / Q000096:biosynthesis; D000419:Albuminuria / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D000818:Animals; D001854:Bone Marrow Cells / Q000276:immunology / Q000378:metabolism; D002465:Cell Movement / Q000276:immunology; D019743:Chemokines, CXC / Q000096:biosynthesis; D004731:Endotoxins / Q000008:administration & dosage / Q000097:blood; D005920:Glomerular Mesangium / Q000276:immunology / Q000378:metabolism; D005921:Glomerulonephritis / Q000235:genetics / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*; D007074:Immunoglobulin G / Q000378:metabolism; D007275:Injections, Intravenous; D007678:Kidney Glomerulus / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*; D007958:Leukocyte Count; D055666:Lipopeptides; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D053594:Myeloid Differentiation Factor 88; D009504:Neutrophils / Q000473:pathology; D010455:Peptides / Q000008:administration & dosage; D012720:Severity of Illness Index; D051195:Toll-Like Receptor 2 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000172:deficiency / Q000502:physiology*
D048868:Adaptor Proteins, Signal Transducing; D019743:Chemokines, CXC; D004731:Endotoxins; D007074:Immunoglobulin G; D055666:Lipopeptides; C507780:Myd88 protein, mouse; D053594:Myeloid Differentiation Factor 88; C508075:Pam(3)CSK(4) peptide; D010455:Peptides; D051195:Toll-Like Receptor 2